Journal of Clinical Oncology · 2015 · 35 citations · 0 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMedical OncologyAdjuvant ChemotherapyCombination ChemotherapyOvarian CancerOvarian Cancer PharmacotherapyCapecitabine-based TherapyClinical Trial ReportsCombination TherapyMucinous Ovarian TumorsOvarian Cancer ChemotherapyOvarian Cancer Clinical TrialsOxaliplatin-based TherapyRecurrent Disease Therapy
5528 Background: Advanced mEOC responds poorly to standard therapy. It comprises < 8% pts in ovarian cancer trials, so it is difficult to examine treatment effects in this subgroup. We conducted the first ever randomised trial specific for this rare subgroup (4 regimens). Methods: mEOC/GOG 241 is a multi-centre randomised phase II trial (UK, USA) in chemo- naive pts with advanced/recurrent disease. Six 21-day cycles of chemotherapy were given to each of 4 arms: (A) carboplatin (AUC 5/6) + paclitaxel (175mg/m2); (B) oxaliplatin (130 mg/m2) + capecitabine (850mg/m2 bd; D1-14); (C) carboplatin/paclitaxel with bevacizumab (15mg/kg); (D) oxaliplatin/capecitabine with bevacizumab. Bevacizumab was given concurrently, then alone 3-weekly for 12 more cycles. 332 pts required to detect 5 month increase in median PFS for oxaliplatin/capecitabine (B+D), or adding bevacizumab (C+D). Results: Trial stopped early (2013) due to poor accrual (median follow up 23 months; 31 progressions/deaths). 50 pts recruited: n = 13, 13, 11, 13 in arms A-D. Median age 54 yrs; FIGO stage II (n = 15), III (n = 25), IV (n = 4), recurrent (n = 6); ECOG 0 (n = 34), 1 (n = 15), 2 (n = 1). 62, 85, 82, 69% in arms A-D completed 6 cycles of combination therapy, and 36, 46% completed 12 maintenance cycles of bevacizumab (arms C,D). 2,2,4,2 pts (arms A-D) had complete/partial response. Median PFS 10.1 (B+D) vs 15.4 (A+C) months; hazard ratio (HR) 1.08, 95% CI 0.53-2.19, p = 0.83. Median PFS 17.4 (C+D) vs 8.8 (A+B) months, HR 0.88 95% CI 0.43-1.79, p = 0.72. Grade 3-4 toxicities (most common: neutropenia, & hypertension for bevacizumab) were seen in 62, 62, 55, 92% pts in arms A-D (total 4 pts with grade 4). After specialist pathology review n = 36 so far, 19 were considered to not have primary mEOC (many metastatic disease). Conclusions: Setting up & conducting this international trial was challenging in this rare group; correctly assigning histological diagnosis was difficult. Bevacizumab may delay progression (ITT analyses), but without sufficient pts no conclusions can be made. Primary mEOC is rarer than previously thought so different approaches are needed to evaluate new therapies. Clinical trial information: NCT01081262.